Ansgar Weltermann
Overview
Explore the profile of Ansgar Weltermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikoloudis A, Bauhofer A, Griessl L, Habermehl A, Groiss C, Binder M, et al.
Cytotherapy
. 2025 Jan;
PMID: 39755976
Background Aims: In HLA-identical hematopoietic stem cell transplantation (HSCT), HLA-C1 group killer cell immunoglobulin-like receptor (KIR) ligands have been linked to graft-versus-host disease, whereas C2 homozygosity was associated with increased...
2.
Bartsch R, Berghoff A, Furtner J, Marhold M, Bergen E, Roider-Schur S, et al.
Neuro Oncol
. 2024 Jul;
26(12):2305-2315.
PMID: 38963808
Background: Brain metastases (BM) are a devastating complication of HER2-positive metastatic breast cancer (BC) and treatment strategies providing optimized local and systemic disease control are urgently required. The antibody-drug conjugate...
3.
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, et al.
Cytotherapy
. 2024 Feb;
26(5):490-497.
PMID: 38385908
Background Aims: Cyclosporin A (CsA) remains a major component of immunosuppressive regimens applied in allogeneic hematopoietic stem cell transplantation (HSCT). The impact of CsA trough levels during the first weeks...
4.
Strassl I, Nikoloudis A, Machherndl-Spandl S, Buxhofer-Ausch V, Binder M, Wipplinger D, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136284
Background: Despite major treatment advances, multiple myeloma remains incurable. The outcome of patients who are refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies is poor, and improved treatment...
5.
Nikoloudis A, Neumann I, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, et al.
Vaccines (Basel)
. 2023 Oct;
11(10).
PMID: 37896938
(1) Background: mRNA COVID-19 vaccines are effective but show varied efficacy in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients. (2) Methods: A retrospective study on 167 HSCT...
6.
Bauer K, Machherndl-Spandl S, Kazianka L, Sadovnik I, Gultekin S, Suessner S, et al.
Leukemia
. 2023 Sep;
37(11):2250-2260.
PMID: 37673973
Myelodysplastic syndromes (MDS) are myeloid neoplasms presenting with dysplasia in the bone marrow (BM) and peripheral cytopenia. In most patients anemia develops. We screened for genes that are expressed abnormally...
7.
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, et al.
Cells
. 2023 Jul;
12(14).
PMID: 37508496
In allogeneic hematopoietic stem cell transplantation (HSCT), Anti-T-Lymphocyte Globulin (ATLG) may be used for the prevention of severe graft-versus-host disease (GVHD). ATLG targets both the recipient's lymphocytes and those transferred...
8.
Strassl I, Windhager A, Machherndl-Spandl S, Buxhofer-Ausch V, Stiefel O, Weltermann A
J Cancer Res Clin Oncol
. 2023 Mar;
149(10):7113-7123.
PMID: 36877279
Purpose: Polypharmacy is a significant problem in patients with incurable cancer and a method to optimize pharmacotherapy in this patient group is lacking. Therefore, a drug optimization tool was developed...
9.
Bartsch R, Berghoff A, Furtner J, Marhold M, Bergen E, Roider-Schur S, et al.
Nat Med
. 2022 Aug;
28(9):1840-1847.
PMID: 35941372
Trastuzumab deruxtecan is an antibody-drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1...
10.
Machherndl-Spandl S, Vockenhuber T, Binder M, Weltermann A, Apfalter P, Lass-Florl C, et al.
Leuk Lymphoma
. 2022 May;
63(10):2330-2335.
PMID: 35561263
Invasive fungal infections (IFIs) are commonly observed in patients, who are at high risk of severe infections during the neutropenic phase. The aim of this retrospective single-center study was to...